Nuvectis Pharma Inc Dossier - Source-backed chat

Nuvectis Pharma Inc

NVCTNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.16

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $20.72Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $676.4M

Enterprise Value $654.2M

Shares Outstanding 32.6M diluted

Next Earnings Date10 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Nuvectis Pharma is a clinical-stage biopharmaceutical company advancing a highly targeted oncology pipeline. Its lead assets, NXP800 (a GCN2 activator) and NXP900 (a first-in-class YES1/SRC inhibitor), target molecularly defined cancers with significant unmet needs. With a solid cash position of $25.1 million as of Q1 2026, providing a runway into 2027, and multiple clinical catalysts expected from its Phase 1b programs, Nuvectis offers a compelling risk-reward profile for biotechnology investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$22.00

Mean target$31.80

High · most bullish analyst$39.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$5.00

Clinical trials encounter safety concerns or lack of efficacy signals, leading to program delays or terminations. The company is forced to raise capital under unfavorable market conditions, resulting in significant shareholder dilution.

Base CaseCentral scenario

$13.00

NXP900 and NXP800 continue to show acceptable safety profiles and encouraging preliminary efficacy signals in their respective Phase 1b trials. The company successfully manages its cash runway through disciplined spending and opportunistic ATM utilization, maintaining steady progress toward late-stage clinical development.

Bull CaseUpside scenario

$20.00

NXP900 demonstrates robust synergistic efficacy in combination with osimertinib in EGFR-mutant NSCLC and as a monotherapy in YES1/SRC-driven solid tumors, leading to rapid registrational pathways. NXP800 achieves high objective response rates in platinum-resistant, ARID1a-mutated ovarian cancer, triggering breakthrough therapy designation and attracting a major pharmaceutical partnership.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-in-class mechanism of action for NXP900, inhibiting both catalytic and scaffolding functions of YES1/SRC.
Fast Track and Orphan Drug Designations for NXP800 in platinum-resistant, ARID1a-mutated ovarian cancer.
Experienced management team with a strong track record of drug development and strategic transactions.
Robust cash runway extending into 2027, supported by a flexible ATM facility.

Key Investment Risks

Clinical-stage risk with no approved products and zero product revenue.
Dependence on external capital markets to fund long-term operations and late-stage trials.
Intense competition in the oncology space from established biopharmaceutical companies.
Potential clinical trial delays or adverse safety events.

Thesis Invalidation Triggers

Failure of NXP900 to show clinical efficacy in Phase 1b cohorts.
Severe drug-related adverse events leading to clinical holds by the FDA.
Inability to secure additional financing, leading to a severe cash crunch before key readouts.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.